| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/24/2008 | US20080175931 Cosmetic foundation |
| 07/24/2008 | US20080175925 Comprising an antiviral agent (chlorhexidine), an antioxidant agent (reduced glutathione), and an analgesic agent (lidocaine); oral application to mouth tissue; cold sores |
| 07/24/2008 | US20080175924 System and Method For Diagnosis of Neuropsychiatric Disorders |
| 07/24/2008 | US20080175923 Methods and Compositions Related to Regulation of Cytokine Production by Glycogen Synthase Kinase 3 (Gsk-3) |
| 07/24/2008 | US20080175922 Topically treating eye disorders, diseases and inflammation without sensitivity |
| 07/24/2008 | US20080175917 Microparticles containing a H+,K+-ATP-ase inhibitor |
| 07/24/2008 | US20080175916 Advancing distal portion of catheter to existing blood vessel and releasing medicant |
| 07/24/2008 | US20080175914 Inflammatory and/or allergic diseases; cognitive impairment |
| 07/24/2008 | US20080175909 Delivery device containing venlafaxine and memantine and method of use thereof |
| 07/24/2008 | US20080175908 Tablet-in-tablet compositions |
| 07/24/2008 | US20080175906 Levonorgestrel, ionic disintegrant and hydrophilic water insoluble nonionic excipient; emergency contraception; easy, accurate administration |
| 07/24/2008 | US20080175905 Estrogen/serm and estrogen/progestin bi-layer tablets |
| 07/24/2008 | US20080175903 Subsedative dosage form of zopiclone optical isomer; instantaneous and sustained release |
| 07/24/2008 | US20080175902 Methods for slowing the progression of multiple sclerosis |
| 07/24/2008 | US20080175901 Reduced polymorphic conversion; estrogen receptor modulator pharmacokinetics |
| 07/24/2008 | US20080175900 Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| 07/24/2008 | US20080175899 Formulation for promoting sinus health in nasal cavities |
| 07/24/2008 | US20080175897 Dosage forms for administering combinations of drugs |
| 07/24/2008 | US20080175892 fullerene carbon nanotube linking to paclitaxel through polyethylene glycol, serinol, succinimidyl-3-(2-pyridyldithio)-propionate or succinic acid; anticarcinogenic agents treating lung cancer; drug target with antibody; aerosols drug delivery |
| 07/24/2008 | US20080175890 Transdermal delivery systems |
| 07/24/2008 | US20080175887 Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| 07/24/2008 | US20080175886 bioabsorbable coating on implant stents; blend of polyamideester copolymers with a Tg above the Tg of poly(ester amide benzyl ester); deliver bioactive agent paclitaxel, docetaxel, estradiol; high glass transition temperature provides release rate control, shelf life stability, prevent mechanical failure |
| 07/24/2008 | US20080175884 Polymer coatings as carriers for the drug delivery of a methosyaminocarbonyloxy derivative of rapamycin and another drug(s) such as an antiproliferative agent, anticoagulant, etc.; reduces restenosis in vasculature procedures to a level of 0-25%; coronary/periferal stents; grafts ; balloons |
| 07/24/2008 | US20080175882 stent medical device has polythioester homo- or copolymer coatings for deliverying paclitaxel, docetaxel, estradiol, estradiol, nitric oxide donors, superoxide dismutases; short hydrolysis half-life time, allowing the polymer to have tunable degradation rate; biocompatible; drug delivery devices |
| 07/24/2008 | US20080175880 Pyridoxal-5-Phosphate And Stent For The Treatment And Prevention Of Atherosclerosis And Restenosis |
| 07/24/2008 | US20080175873 cores comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, gelling agents and excipients, having sustained release coatings; higher bioavailability and side effect reduction |
| 07/24/2008 | US20080175872 Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid |
| 07/24/2008 | US20080175866 involved in the adaptation of microorganisms to its environment, particularly the identification of genes responsible for the virulence of a pathogenic microorganisms |
| 07/24/2008 | US20080175848 Reducing matrix protein concentration via enzyme inhibitor and plasmin administration; prevention and treatment of fibrosis; wound healing agent |
| 07/24/2008 | US20080175845 Using tumor necrosis factor receptor specific monoclonal antibody as therapeutic for treatment and prevention of inflammatory disorders |
| 07/24/2008 | US20080175842 Compositions and methods for treatment |
| 07/24/2008 | US20080175832 Materials and Methods for Prevention and Treatment of RNA Viral Diseases |
| 07/24/2008 | US20080175831 Neuroprotection by blood flow stabilization |
| 07/24/2008 | US20080175820 Using vascular endothelial growth factor as wound healing agent; tissue engineering; regenerative medicine; wound healing agent |
| 07/24/2008 | US20080175819 Vector system |
| 07/24/2008 | US20080175818 Using replication-defective plasmid comprising p53 nucleotide sequences as as delivery tool for antitumor agents |
| 07/24/2008 | US20080175814 Quinoline derivatives for modulating dna methylation |
| 07/24/2008 | US20080175812 Polymer coatings containing phytochemical agents and methods for making and using same |
| 07/24/2008 | US20080175811 Method and Composition For Use In Preparation of a Patient For Surgery |
| 07/24/2008 | US20080175810 Topical compositions for cosmetic and pharmaceutical use |
| 07/24/2008 | US20080175802 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations |
| 07/24/2008 | US20080175800 Use of specific menthyl 3-oxocarboxylic acid esters as physiologically active cooling substances |
| 07/24/2008 | US20080175797 Preventing airway mucus production by administration of egf-r antagonists |
| 07/24/2008 | US20080175796 Delivery of Drug Esters Through an Inhalation Route |
| 07/24/2008 | US20080175795 e.g. 3-{4-[4-(2-amino-2-carbamoyl-ethyl)-phenoxy]-phenyl)-propionic acid; antiinflammatory and immunological diseases, cytokines (TNF- alpha , IL-1, IL-6), orexin, nitric oxide synthase inhibitor; obesity, hyperlipidemia, migraine, asthma, chronic obstructive pulmonary disease, osteoarthritis |
| 07/24/2008 | US20080175794 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues |
| 07/24/2008 | US20080175789 Prostate specific membrane antigen (PSMA); for diagnosis, detection and treatment of cancer; gene overexpression; kits |
| 07/24/2008 | DE102007027201A1 Conjugates useful for chemotherapy or positron emission tomography comprising a platinum complex and a glucose compound |
| 07/24/2008 | DE102007005580A1 Arzneimittel zur Behandlung von Sepsis Drugs for the treatment of sepsis |
| 07/24/2008 | DE102007003765A1 Pharmazeutische Zusammensetzung zur Behandlung von Inkontinenz A pharmaceutical composition for the treatment of incontinence |
| 07/24/2008 | DE102007002924A1 ß-Lactam-haltige Formulierungen mit erhöhter Stabilität in wässriger Lösung ß-lactam-containing formulations having increased stability in aqueous solution |
| 07/24/2008 | DE102007002717A1 Heterocyclische Indazolderivate Heterocyclic indazole derivatives |
| 07/24/2008 | DE102007002715A1 Triazolderivat Triazole derivative |
| 07/24/2008 | DE102007002410A1 Synthese von Chromanderivaten Synthesis of chroman |
| 07/24/2008 | CA2823905A1 Heterocyclic-substituted piperidine compounds and the uses thereof |
| 07/24/2008 | CA2823883A1 Heterocyclic-substituted piperidine compounds and the uses thereof |
| 07/24/2008 | CA2712109A1 Thiazolidine derivatives and methods for the preparation thereof |
| 07/24/2008 | CA2712073A1 Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use |
| 07/24/2008 | CA2712056A1 Method of inducing an immune response |
| 07/24/2008 | CA2711743A1 Quinazolinone derivatives for treating or preventing skeletal muscle fibrosis |
| 07/24/2008 | CA2686816A1 Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder |
| 07/24/2008 | CA2676444A1 Prodrugs of substituted 1,3-dioxanes and their uses |
| 07/24/2008 | CA2676439A1 Substituted 1,3-dioxanes and their uses |
| 07/24/2008 | CA2676437A1 Substituted 1,3-dioxanes and their uses |
| 07/24/2008 | CA2676435A1 Substituted 1,3-dioxanes useful as ppar modulators |
| 07/24/2008 | CA2676432A1 Inhibitors of d-amino acid oxidase |
| 07/24/2008 | CA2676010A1 Methods and compositions for the delivery of a therapeutic agent |
| 07/24/2008 | CA2675980A1 Use of dast for treatment of cancers with acquired resistance to kit inhibitors |
| 07/24/2008 | CA2675979A1 Treatment of cancers having resistance to chemotherapeutic agents |
| 07/24/2008 | CA2675968A1 Oligosaccharides comprising an aminooxy group and conjugates thereof |
| 07/24/2008 | CA2675836A1 Composition for preventing or treating thrombus- or embolus-associated disease |
| 07/24/2008 | CA2675834A1 Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors |
| 07/24/2008 | CA2675797A1 Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
| 07/24/2008 | CA2675760A1 Treatment of pain with naloxone |
| 07/24/2008 | CA2675755A1 Kinase inhibitor compounds |
| 07/24/2008 | CA2675743A1 Phenazine compounds and use thereof in autoimmune and inflammatory diseases |
| 07/24/2008 | CA2675737A1 Triazole derivative |
| 07/24/2008 | CA2675736A1 Composition for treatment of pancreatic cancer |
| 07/24/2008 | CA2675735A1 5-(1,3,4-oxadiazol-2-yl)-1h-indazole and 5-(1,3,4-thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes |
| 07/24/2008 | CA2675733A1 Method for glycosylation of flavonoid compounds |
| 07/24/2008 | CA2675676A1 Nicotinic acetylcholine receptor modulators |
| 07/24/2008 | CA2675583A1 Inflammation treatment, detection and monitoring via trem-1 |
| 07/24/2008 | CA2675520A1 New combination for use in the treatment of inflammatory disorders |
| 07/24/2008 | CA2675443A1 Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| 07/24/2008 | CA2675442A1 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome |
| 07/24/2008 | CA2675419A1 Heterocyclic-substituted piperidine compounds and the uses thereof |
| 07/24/2008 | CA2675374A1 Formulations for parenteral administration of amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones |
| 07/24/2008 | CA2675358A1 Inhibitors of mek |
| 07/24/2008 | CA2675252A1 N-substituted glycine derivatives: hydroxylase inhibitors |
| 07/24/2008 | CA2675246A1 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives |
| 07/24/2008 | CA2675176A1 Levosimendan for use in treating chronic valvular disease |
| 07/24/2008 | CA2675134A1 Pterin analogs |
| 07/24/2008 | CA2675117A1 Iron-carbohydrate complex compounds with at least 2 wt% of total iron as iron(ii) |
| 07/24/2008 | CA2675016A1 Pharmaceuticals, compositions and methods of making and using the same |
| 07/24/2008 | CA2674949A1 Targeting ncca-atp channel for organ protection following ischemic episode |
| 07/24/2008 | CA2674946A1 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| 07/24/2008 | CA2674865A1 Indole derivative having i.kappa.b kinase .beta. inhibitory activity |
| 07/24/2008 | CA2674698A1 New classical antifolates |
| 07/24/2008 | CA2674683A1 Compositions and methods for treatment of colorectal cancer |
| 07/24/2008 | CA2674678A1 Morpholine dopamine agonists for the treatment of pain |